

Conclusion

With appropriate performing of cytogenetic and molecular tests for ALL diagnosis, treatment strategies might be modified and specified for each patient and the efficacy of new therapeutic strategies could be evaluated accurately. Genetic polymorphism affects drug metabolism and leads to different effective levels and drug toxicity.

Acknowledgement

We would like to thank Clinical Research Development Center of Ghaem Hospital for their assistant in this manuscript. This study was supported by a grant from the Vice Chancellor for Research of the Mashhad University of Medical Sciences for the research project as a medical student thesis with approval number of 910347.

Conflict of Interest

The authors declare no conflict of interest.

References

1. H Ronald Hoffman BF, Philip McGlave, Leslie ES, Sanford JS, Edward JB Jr, Helen H. Hematology: Basic Principles and Practice, 5th ed. Philadelphia: Churchill Livingstone; 2009.
2. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood*. 2010;115:3206–3214.
3. Khalid S, Moiz B, Adil SN, et al. Retrospective review of pediatric patients with acute lymphoblastic leukemia: a single center experience. *Indian J Pathol Microbiol*. 2010; 53:704-710.
4. Braoudaki M, Lambrou GI, Vougas K, et al. Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner. *J Hematol Oncol*. 2013;6:52.
5. Assumpção JG, Paula FD, Xavier SG, et al. Gene rearrangement study for minimal residual disease monitoring in children with acute lymphocytic leukemia. *Rev Bras Hematol Hemoter*. 2013;35:337-342.
6. Kiyokawa N, Iijima K, Tomita O, et al. Significance of CD66c expression in childhood acute lymphoblastic leukemia. *Leuk Res*. 2014;38:42-48.
7. Vitale A, Guarini A, Ariola C, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. *Haematologica*. 2007;92:342-348.
8. Zhao Y, Huang H, Wei G. Novel agents and biomarkers for acute lymphoid leukemia. *J Hematol Oncol*. 2013; 18;6:40.
9. Niedzielska E, Węclawek-Tompol J, Matkowska-Kocjan A, et al. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate. *Adv Clin Exp Med*. 2013; 22:579-584.
10. Mazloumi SH, Madhumathi DS, Appaji L, et al. Combined study of cytogenetics and fluorescence in situ hybridization (FISH) analysis in childhood acute lymphoblastic leukemia (ALL) in a tertiary cancer centre in South India. *Asian Pac J Cancer Prev*. 2012;13:3825-3827.
11. Bhojwani D, Howard SC, Pui CH. High-risk childhood acute lymphoblastic leukemia. *Clin Lymphoma Myeloma*. 2009;9:S222-230.
12. Matutes E, Morilla R, Farhat N, et al. Definition of acute biphenotypic leukemia. *Haematologica*. 1997;82:64-66.
13. McGregor S, McNeer J, Gurbuxani S. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. *Semin Diagn Pathol*. 2012;29:2-11.
14. Mi JQ, Wang X, Yao Y, et al. Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases. *Leukemia*. 2012;26:1507-1516.
15. Patkar N, Alex AA, B B, Ahmed R, Abraham A, George B, et al. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. *Cytometry B Clin Cytom*. 2012;82:252-258.
16. Settin A, Al Haggag M, Al Dosoky T, et al. Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia: cases from Mansoura, Egypt. *Hematology*. 2006;11:341-349.